.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Deloitte
US Department of Justice
Accenture
McKesson
Cerilliant
US Army
Citi
Chinese Patent Office
QuintilesIMS

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,050,308

« Back to Dashboard

Which drugs does patent 9,050,308 protect, and when does it expire?


Patent 9,050,308 protects EPANOVA and is included in one NDA.

This patent has twenty-four patent family members in twenty-one countries.

Summary for Patent: 9,050,308

Title:DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Inventor(s): Maines; Timothy J. (Potomac, MD), Machielse; Bernardus N M (North Potomac, MD), Mehta; Bharat M. (Mendham, NJ), Wisler; Gerald L. (Windermere, FL), Davidson; Michael H. (Highland Park, IL), Wood; Peter Ralph (Cotherstone, GB)
Assignee: Omthera Pharmaceuticals, Inc. (Princeton, NJ) Chrysalis Pharma AG (Sacheln, CH)
Application Number:13/734,846
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
EPANOVA
omega-3-carboxylic acids
CAPSULE;ORAL205060-001May 5, 2014RXYesYes► Subscribe► Subscribe TREATMENT OF HYPERTRIGLYCERIDEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,050,308

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,050,309DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,050,308

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China104321055► Subscribe
China107050457► Subscribe
Colombia7061070► Subscribe
Costa Rica20140350► Subscribe
Dominican RepublicP2014000159► Subscribe
European Patent Office2800563► Subscribe
Hong Kong1202073► Subscribe
Israel233517► Subscribe
India6125DEN2014► Subscribe
Japan2015503590► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Dow
Colorcon
Covington
Argus Health
Cerilliant
UBS
Fish and Richardson
Moodys
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot